诺华报称,销售额猛增15%,达到132亿美元,超出预期,计划进行美国的重大投资。 Novartis reports a 15% sales jump to $13.2 billion, exceeds expectations, and plans major U.S. investments.

瑞士一家制药公司Novartis报告说,2025年第一季度情况强劲,销售额增长15%,达132亿美元,超过了预期。 Novartis, a Swiss pharmaceutical company, reported a strong first quarter in 2025 with a 15% increase in sales to $13.2 billion, surpassing expectations. 关键驱动因素包括对诸如Entresto、Kisqali、Kesimpta和Leqvio等药物需求的增加。 Key drivers included increased demand for drugs like Entresto, Kisqali, Kesimpta, and Leqvio. 该公司提高了全年指导,预测了高一位数销售增长和低两位数核心业务收入增长。 The company raised its full-year guidance, forecasting high single-digit sales growth and low double-digit growth in core operating income. Novartis还计划在五年内投资230亿美元,在美国建造或扩建10个设施。 Novartis also plans to invest $23 billion over five years to build or expand 10 facilities in the U.S.